Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
For advanced head and neck cancer, combined radiation and chemotherapy prevents recurrences
and for many patients, improves survival. While combined cisplatin and radiation or cetuximab
and radiation is more effective than radiation alone, approximately 50% of these patients
will still recur. A more aggressive approach may be needed for these patients to prevent
recurrence and death. The strategy of using multiple chemotherapy drugs with radiation given
twice a day has been tested at Mount Sinai and University of Chicago. Approximately 80% of
patients are cured with this strategy. While cure rates are higher than standard chemotherapy
and radiation and the treatment is tolerable, side effects during treatment are common. We
propose replacing a chemotherapy drug with a less toxic, targeted therapy called cetuximab.
Our goal is to reduce toxicity while maintaining or improving cure rates for these patients.
Phase:
Phase 2
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai Johnny Kao